Atai Life Sciences Retained Earnings (Accumulated Deficit) 2020-2024 | ATAI
Atai Life Sciences retained earnings (accumulated deficit) from 2020 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Atai Life Sciences Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-551 |
| 2022 |
$-510 |
| 2021 |
$-358 |
| 2020 |
$-190 |
| 2019 |
$-20 |
Atai Life Sciences Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-09-30 |
$-661 |
| 2024-06-30 |
$-635 |
| 2024-03-31 |
$-578 |
| 2023-12-31 |
$-551 |
| 2023-09-30 |
$-533 |
| 2023-06-30 |
$-577 |
| 2023-03-31 |
$-544 |
| 2022-12-31 |
$-510 |
| 2022-09-30 |
$-465 |
| 2022-06-30 |
$-431 |
| 2022-03-31 |
$-395 |
| 2021-12-31 |
$-358 |
| 2021-09-30 |
$-269 |
| 2021-06-30 |
$-238 |
| 2021-03-31 |
$-189 |
| 2020-12-31 |
$-190 |
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
$-20 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$0.305B |
$0.000B |
|
atai Life Sciences B.V. is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai Life Sciences B.V. is based in BERLIN.
|
